Journal ArticleDOI
Gram-positive infections: pharmacy issues and strategy for quinupristin/dalfopristin.
John C. Rotschafer,John C. Rotschafer,David H. Wright,David H. Wright,Gigi H. Brown,Gigi H. Brown +5 more
Reads0
Chats0
TLDR
The development of the first streptogramin antibiotic, quinupristin/dalfopristin represents an attempt to bring new antimicrobial strategies on line to combat the menacing problem of Gram-positive-resistant bacteria.About:
This article is published in Diagnostic Microbiology and Infectious Disease.The article was published on 1999-02-01. It has received 9 citations till now. The article focuses on the topics: Dalfopristin & Quinupristin.read more
Citations
More filters
Journal ArticleDOI
Drug discovery in the next decade: innovation needed ASAP
TL;DR: A general perspective from within pharmaceutical research as it pertains to research advances in chemistry, biology, pharmacology, pharmacokinetics and toxicology that, if well integrated, stands to put the industry on a productive path.
Journal ArticleDOI
Quinupristin-Dalfopristin: An Overview
TL;DR: Synercid (RP 59500), the first injectable streptogramin antibiotic, is composed of two semisynthetic pristinamycin derivatives, quinupristin and dalfopristin, which appears to have a role in treating severely ill patients with infections due to multiresistant gram‐positive pathogens.
Journal ArticleDOI
Treatment of Vancomycin-Resistant Enterococcus with Quinupristin/Dalfopristin and High-Dose Ampicillin
TL;DR: Persistent VRE bacteremia was successfully treated in this neutropenic patient and case reports and in vitro data suggest that concomitant therapy with high-dose ampicillin may be an effective treatment alternative for VRE infections not responding to standard therapy.
Journal ArticleDOI
Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections
TL;DR: The chemistry, mechanism of action, pharmacokinetic properties and spectrum of microbiological activity of iclaprim, a novel dihydrofolate reductase inhibitor recently awarded fast-track approval status by the FDA, are described.
Posted ContentDOI
Depiction of secondary metabolites and antifungal activity of Bacillus velezensis DTU001
Sagarika Devi,Heiko T. Kiesewalter,Renátó Kovács,Jens Christian Frisvad,Tilmann Weber,Thomas Ostenfeld Larsen,Ákos T. Kovács,Ling Ding +7 more
TL;DR: A new Bacillus velezensis strain DTU001 is isolated, investigated its antifungal spectrum, sequenced its genome, and uncovered the production of lipopeptides in HPLC-HRMS analysis that might assist aims to avoid hazardous pathogenic fungi and provide alternative to toxicity caused by chemicals.
References
More filters
Journal ArticleDOI
Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus
TL;DR: Conjugative transfer, in the apparent absence of plasmid DNA, of high-level vancomycin resistance from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus B111 has been demonstrated and transfer of erythromycin and of chloramphenicol resistance has been achieved.
Journal Article
Recommendations for preventing the spread of vancomycin resistance
TL;DR: A rapid increase in the incidence of infection and colonization with vancomycin-resistant enterococci (VRE) has been reported from U.S. hospitals in the last 5 years as discussed by the authors.
Interscience Conference on Antimicrobial Agents and Chemotherapy
Aki Okazaki,Matthew B Avison +1 more
Journal ArticleDOI
RP 59500: a proposed mechanism for its bactericidal activity
TL;DR: It is proposed that the mechanism of action of these compounds is to close or narrow the extrusion channel of these proteins, which could lead to their accumulation on the ribosome, thereby depleting free tRNAs within the cell and inhibiting protein synthesis.
Related Papers (5)
Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination.
Samuel Matsumura,Andrew E. Simor +1 more